Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
Clinical Cancer Research 2024; 30(14):2917-2924
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer
Cancer Discovery 2021 Oct;11(10):2436-2445.
REDD1 loss reprograms lipid metabolism to drive progression of RAS mutant tumors
Genes Dev 2020 Jun 1;34(11-12):751-766.
Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers
Sciences Advances 2020 Jan 29;6(5):eaay2611.
Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq.
Nature Communications 2018 Sep 4;9(1):3588
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.
Cancer Discovery 2018 8 (3) :336-353.
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Nat Genet 2017 Oct;49(10):1476-1486.
Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1.
Developmental Cell 2014; 28:147-60.